Armistice Capital’s Sophiris Bio, Inc. SPHS Stock Holding History

Armistice Capital’s Portfolio SPHS Stock Details SPHS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,793,666	Closed	-$2.21M	–	97
2019 Q3	$2.21M	Buy	+1,793,666	New	+$1.59M	0.15%	60

Other funds holding SPHS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Armistice Capital's SPHS Position: Q4 2019 in Review

Armistice Capital sold out of Sophiris Bio, Inc. (SPHS) in Q4 2019, closing a stake of 1,793,666 shares — an estimated $2.21M sold.

Armistice Capital first reported a position in SPHS in Q3 2019 and held it in 1 quarter. The position peaked at $2.21M in Q3 2019. 27 funds tracked by Wall St. Rank hold SPHS as of Q4 2019.

Armistice Capital reported no remaining Sophiris Bio, Inc. position as of Q4 2019 after selling out during the quarter.
Armistice Capital sold 1,793,666 Sophiris Bio, Inc. shares in Q4 2019, an estimated $2.21M.
Armistice Capital first reported a position in Sophiris Bio, Inc. in Q3 2019 and held it in 1 quarter.
Armistice Capital's Sophiris Bio, Inc. position peaked at $2.21M in Q3 2019.
27 funds tracked by Wall St. Rank held Sophiris Bio, Inc. as of Q4 2019.

Based on Armistice Capital's 13F filing for Q4 2019, filed 14 Feb 2020.